![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
X
20
Linnea S.a. Lavertezzo Ch, based in Switzerland, is a pharmaceutical company.
One of their significant offerings is Hyoscine butylbromide, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2017-296 - Rev 00
This Chemical Type CEP, issued on April 19, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 737 associated with this CEP further emphasizes